Phaseline

Targets › MICA

MICA (MHC class I polypeptide-related sequence A): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Mar 2027.

Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8 alphabeta T-cells. Up-regulated in stressed conditions, such as viral and bacterial infections or DNA damage response, serves as signal of cellular stress, and engagement of KLRK1/NKG2D by MICA triggers NK-cells…. (UniProt, Q29983)

Open in Phaseline: the race on MICA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cullinan TherapeuticsCLN-619
Anti-MICA/MICB monoclonal antibody
MICA, MICBPhase 1Advanced Solid Tumor; Multiple MyelomaMar 2027
D2M BiotherapeuticsDM919
Anti-MICA/MICB monoclonal antibody
MICA, MICBPhase 1Advanced Solid Tumor–

Conditions

Advanced Solid Tumor (2) Multiple Myeloma (1)

Modalities

mixed (2)

Companies

D2M Biotherapeutics (1) Cullinan Therapeutics (1)

Related targets

MICB (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.